Biogen has started a phase 3 trial that it hopes will extend the label for its Skyclarys therapy for inherited neurological disease Friedreich's ataxia (FA) to include children as young as two.

– Late-breaking presentation at ESC Congress 2025 confirms that early, persistent lowering of LDL-C and blood pressure leads to improved cardiovascular health outcomes – – Raised over $50 million to ...